# A Study of LY2216684 in Major Depressive Disorder in Patients Taking Selective Serotonin Reuptake Inhibitors

> **NCT01263223** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 24 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** LY2216684
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01263223
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2018-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01263223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01263223, "A Study of LY2216684 in Major Depressive Disorder in Patients Taking Selective Serotonin Reuptake Inhibitors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01263223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*